Back to Peptide Index

Tesamorelin

MetabolicEvidence Level: clinicalFDA-approved for HIV-associated lipodystrophy; broader applications remain under clinical investigation.
Peptide #45

Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, meaning it stimulates the body’s production of growth hormone (GH). It is FDA-approved for reducing excess visceral fat in HIV patients with lipodystrophy and is being studied for its potential to improve body composition, support muscle health, and promote healthy aging.

Alternative Names:

Egrifta®

Overview

Tesamorelin is a synthetic peptide that helps the body naturally boost growth hormone levels. It is FDA-approved for reducing belly fat in people with HIV and is being studied for its potential to improve body composition, support muscle health, and promote healthy aging.

How It Works

Tesamorelin significantly enhances the physiological secretion of growth hormone, providing a natural pattern of hormone release. It targets and reduces visceral fat accumulation, improves insulin sensitivity, metabolic function, cognitive performance, and general energy levels.

Clinical Effects

Improves metabolism, increases lean muscle mass, reduces body fat, enhances metabolic and cognitive health, improves insulin sensitivity, and reduces cardiovascular risks.

Therapeutic Applications

HIV-associated lipodystrophy, metabolic syndrome, cognitive and physical health, anti-aging and longevity.

Research Studies

Clinical Trials

Numerous human clinical trials have confirmed Tesamorelin’s effectiveness in visceral fat reduction, improved metabolic health, and body composition enhancement.

Frequently Asked Questions

Is Tesamorelin legally available? Tesamorelin is FDA-approved specifically for treating HIV-associated lipodystrophy and legally available for research purposes from specialized suppliers. Have human trials been conducted with Tesamorelin? Numerous human clinical trials have confirmed Tesamorelin’s effectiveness in visceral fat reduction, improved metabolic health, and body composition enhancement, with further studies ongoing for broader applications. What are potential side effects of Tesamorelin? Commonly reported side effects include injection site reactions, mild swelling, muscle discomfort, and occasionally fluid retention. Long-term safety assessments are still in progress. How is Tesamorelin typically administered? Tesamorelin is generally administered via subcutaneous injections, with specific dosages tailored to individual therapeutic objectives and clinical research protocols. Can Tesamorelin be combined with other treatments? Combination therapy involving Tesamorelin requires controlled clinical studies to establish safe, effective, and optimized therapeutic protocols. Does Tesamorelin provide permanent visceral fat reduction? Tesamorelin effectively reduces visceral fat during active treatment periods. Sustained benefits typically require ongoing therapy combined with lifestyle adjustments.

Quick Information

Safety Information

Safety Profile

Long-term safety assessments are still in progress.

Contraindications

Side Effects: Injection site reactions, mild swelling, muscle discomfort, fluid retention. Safety Profile: Long-term safety assessments are still in progress.

Side Effects

Injection site reactions, mild swelling, muscle discomfort, fluid retention.

Research References

Stanley, T.L., & Grinspoon, S.K. (2015). Body composition and metabolic changes associated with HIV-associated lipodystrophy. Clinical Infectious Diseases. Falutz, J., et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes. Makimura, H., & Feldpausch, M.N. (2010). Clinical potential of tesamorelin in the management of HIV-associated lipodystrophy. HIV/AIDS - Research and Palliative Care.

Additional Resources